Stocks Extend Slump, Treasury Yields Climb 

Hot monthly retail sales and Middle East tensions weigh on indexes, with the S&P 500 falling 1.2%.

Oil's rally took a breather after Iran's attack on Israel. Is $100 a barrel still in the cards? 

Oil's climb toward $100 a barrel came to a halt on Monday, but whether the market is taking a temporary breather from its rally or has hit a long-term snag remains to be seen.

Gold scores another record high as market awaits Israel response to Iran attack 

Gold futures eke out a gain on Monday to notch a fresh record-high settlement as traders awaited Israel's response after Iran's attack over the weekend.

Retail sales rose sharply in the first quarter - and could boost U.S. GDP 

Sales at retailers rose a robust 0.7% in March and outlays in February were also stronger than initially reported, indicating the economy got a decent boost from consumer spending in the first quarter.

Israel's Next Move After Iran Attack Involves Complex Calculations 

Decision makers must balance the need to deter Iran with the desire to strengthen a tenuous government coalition and achieve their war aims in Gaza.

Corporate Canada Braces for Higher Taxes in Tuesday's Budget Plan 

The business groups and economists worry that higher taxes could pose another hurdle to the country's lackluster business investment.

Here's What Higher for Longer Means for the Stock Market 

Stocks are still trading near record levels, but some investors say further gains may be more difficult to come by.

Trucking Oversupply Is Weighing on Carriers' Earnings Outlooks 

A push by retailers and manufacturers to cut shipping costs is sending trucking industry hopes of an earnings rebound into a skid.

China's Central Bank Holds Key Policy Rates 

The People's Bank of China kept key policy rates steady and drained liquidity from the banking sector as economic data shows fresh signs of weakness.

Certain Biotech Investors Get an Early Look at Results. Is That Fair? 

Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.

(END) Dow Jones Newswires

04-15-24 2115ET